Compare NKTX & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKTX | FT |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 178.7M |
| IPO Year | 2020 | N/A |
| Metric | NKTX | FT |
|---|---|---|
| Price | $1.53 | $7.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 58.0K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | ★ 11.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $6.95 |
| 52 Week High | $3.72 | $8.35 |
| Indicator | NKTX | FT |
|---|---|---|
| Relative Strength Index (RSI) | 21.27 | 60.91 |
| Support Level | N/A | $6.95 |
| Resistance Level | $1.88 | $8.32 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 10.32 | 91.17 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.